PLK

Polo-like kinase (PLK) is a highly conserved serine/threonine protein kinase with a highly homologous serine/threonine kinase domain at its N-terminus, which regulates PLK activity and subcellular dynamics at the C-terminus and targeted polo-box domain (PBD). There are many PLK family members, and there are four subtypes in the human body, namely PLK1, PLK2, PLK3, and PLK4, which play important roles in the regulation of various phases of the cell cycle.

Cat No.	product name
T0973	Pyridoxine	Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Although pyridoxine and vitamin B6 are still frequently u...
T2271	SBE 13 hydrochloride	SBE13 hydrochloride is an effective and specific PLK1 inhibitor (IC50: 0.2 nM); no inhibition om Aurora A kinase, Plk2/3.
T2438	HMN214	HMN-214(IVX214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.
T2634	RO 3280	Ro3280 is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).
T2704	MLN0905	MLN0905 is an effective PLK1 inhibitor(IC50=2 nM).
T6019	VolasertibHOT	Volasertib (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM).
T6173	BI 2536HOT	BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.
T6247	NMS-P937	NMS-P937 (NMS1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher ove...
T6282	GSK461364	GSK461364(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.
T7200	TAK-960	TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.
T5818	ON-01910	Rigosertib, a non-ATP-competitive inhibitor of PLK1(IC50=9 nM), exhibits 30-fold higher specificity activity over Plk2 and no effect on Plk3.
T16559	Poloxime	Poloxime is a hydrolysis product of poloxin and is a non-ATP-competitive Plk1 inhibitor. It also has moderate Plk1 inhibitory activity.
T16560	Poloxin	Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM).
T16750	Rigosertib	Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, whic...
T17008	TC-S 7005	TC-S 7005 is an inhibitor of Polo-like kinases (IC50s: 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively).
TN3247	7-O-Prenylscopoletin	7-O-Prenylscopoletin and cedrelopsin show high antiproliferative activities against cancer cell lines.

Cat No.

product name

T0973

Pyridoxine

Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Although pyridoxine and vitamin B6 are still frequently u...

T2271

SBE 13 hydrochloride

SBE13 hydrochloride is an effective and specific PLK1 inhibitor (IC50: 0.2 nM); no inhibition om Aurora A kinase, Plk2/3.

T2438

HMN214

HMN-214(IVX214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.

T2634

RO 3280

Ro3280 is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).

T2704

MLN0905

MLN0905 is an effective PLK1 inhibitor(IC50=2 nM).

T6019

VolasertibHOT

Volasertib (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM).

T6173

BI 2536HOT

BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.

T6247

NMS-P937

NMS-P937 (NMS1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher ove...

T6282

GSK461364

GSK461364(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.

T7200

TAK-960

TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.

T5818

ON-01910

Rigosertib, a non-ATP-competitive inhibitor of PLK1(IC50=9 nM), exhibits 30-fold higher specificity activity over Plk2 and no effect on Plk3.

T16559

Poloxime

Poloxime is a hydrolysis product of poloxin and is a non-ATP-competitive Plk1 inhibitor. It also has moderate Plk1 inhibitory activity.

T16560

Poloxin

Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM).

T16750

Rigosertib

Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, whic...

T17008

TC-S 7005

TC-S 7005 is an inhibitor of Polo-like kinases (IC50s: 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively).

TN3247

7-O-Prenylscopoletin

7-O-Prenylscopoletin and cedrelopsin show high antiproliferative activities against cancer cell lines.